R&D
AstraZeneca and Amgen’s Tezspire Hits in Esophagus Disease, Eyeing Dupixent’s Turf
The TSLP-blocking antibody met its goals in a Phase 3 eosinophilic esophagitis trial, setting up a potential third indication and a challenge to Sanofi’s Dupixent.